You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥股低位不乏買盤 藥明生物、君實及康希諾午後升幅曾擴至14%-40%
雖然康希諾-B(06185.HK)預期吸入用新冠疫苗不會帶來公司業績大幅增長兼遭富瑞降評級至「跑輸大市」及大削目標價至106元。但該股繼昨天由逾七個月高位急吐35%後,今天重越牛熊線(103.3元),午後初段最多回升40%高見128.6元遇壓,現報108.4元,回升18%;康希諾A(688185.SH)回升15%收247.88元人民幣。 其餘醫藥股繼昨天調整後,低位也不乏買盤,尤其是藍籌藥明生物(02269.HK)回吐守穩10天線,午後股價曾漲14%高見44.9元,現報43.4元,回升11%。君實生物(01877.HK)午後曾急彈20%高見35.1元,現報32.6元,回升12%。 藍籌石藥(01093.HK)/中生製藥(01177.HK)、三葉草生物(02197.HK)、復星醫藥(02196.HK)及歌禮製藥(01672.HK)回漲約5%-8%。 昨天逆市續追落後的百濟神州(06160.HK)、信達生物(01801.HK)、泰格醫藥(03347.HK)及康龍化成(03759.HK)續升逾2.5%-7.5%,分別高見115.3、32.3元、69.2元及36.75元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account